ClinicalTrials.Veeva

Menu

Ultrasound-guided Femoral Puncture to Reduce Access- Related Complications After TAVR: (ACCESS-TAVR SIRIO)

F

Fondazione Toscana Gabriele Monasterio

Status

Enrolling

Conditions

Transcatheter Aortic Valve Replacement

Treatments

Procedure: US-guided femoral puncture vs Fluoroscopy-guided puncture

Study type

Interventional

Funder types

Other

Identifiers

NCT05637983
Versione: 1.0 del 18/06/2020

Details and patient eligibility

About

Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)-guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system.

We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.

Full description

Transfemoral approach has become the standard route for a transcatheter aortic valve replacement (TAVR) procedure. Despite the technology improvements, vascular complications and access-related bleeding are frequently observed after TAVR and emerge predominantly within 30 days after TAVR. Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)- guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system.

We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.

Enrollment

508 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Eligible Patients are male or female with severe aortic stenosis evaluated by the Heart Team as candidate to TAVR based on the current cardiology guidelines.

Exclusion criteria

  • Refusal to participate in the study;
  • Inability to provide written consent to the study protocol;
  • Chronic immuno-suppressant therapy;
  • Any concomitant condition which, in the opinion of the Investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological disorder);
  • Enrolment in another study that could confound the results of this study;
  • Life expectancy < 1 year;
  • Any contraindication to TAVR procedure;
  • Non transfemoral TAVR.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

508 participants in 2 patient groups

US-guided femoral puncture
Experimental group
Description:
US-guided femoral puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
Treatment:
Procedure: US-guided femoral puncture vs Fluoroscopy-guided puncture
Fluoroscopy-guided puncture
Active Comparator group
Description:
Fluoroscopy-guided puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
Treatment:
Procedure: US-guided femoral puncture vs Fluoroscopy-guided puncture

Trial contacts and locations

1

Loading...

Central trial contact

Sergio Berti, MD; Eliano Navarese, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems